Cytokinetics

Cardiovascular Account Specialist - U.S. Sales, Kansas City, KS

Remote

Auto‑apply with AI Apply

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, PharmaceuticalsIndustries

Requirements

Candidates are required to possess a Bachelor's degree and at least 5 years of experience in biotech or pharmaceutical sales, with a preference for experience as a territory rep with sole ownership. Cardiology, rare disease, or specialty product experience is preferred, along with experience in specialty product launches.

Responsibilities

As a Cardiovascular Account Specialist, you will be responsible for introducing Cytokinetics in your territory and launching its first commercial product, a novel cardiac myosin inhibitor for Hypertrophic Cardiomyopathy (HCM). This includes developing territory-specific account plans, identifying and developing strategic IDNs and Hospitals, cardiology clinics, and specialty pharmacies, and serving as a resource within these care settings. You will also be responsible for communicating approved resources to HCPs, demonstrating strategic thinking, and proactively supporting the company’s mission to address patients’ unmet needs.

Skills

Biotech/Pharma Sales

Cardiology

Rare Disease

Specialty Product Launch

Account Planning

Customer Collaboration

Disease and Product Knowledge

Demand Generation

Cytokinetics

Develops drugs for muscle function disorders

About Cytokinetics

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a pipeline of drugs, including omecamtiv mecarbil and reldesemtiv, which are in various stages of clinical trials. Unlike many competitors, Cytokinetics emphasizes rigorous scientific research and has conducted over 50 clinical trials to ensure the effectiveness of its treatments. The goal is to bring new therapies to market that address the unmet needs of patients suffering from conditions like heart failure, ALS, and HCM.

Key Metrics

South San Francisco, CaliforniaHeadquarters

1998Year Founded

$58.4MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

501-1,000Employees

Risks

Increased competition could impact market share and profitability.

Potential delays in clinical trials could hinder drug commercialization.

Dependence on strategic partnerships may expose Cytokinetics to risks if challenges arise.

Differentiation

Cytokinetics focuses on muscle activators and inhibitors for cardiovascular and neuromuscular diseases.

The company has a robust pipeline including omecamtiv mecarbil and aficamten.

Cytokinetics engages in strategic partnerships, like with Sanofi, to expand market reach.

Upsides

Recent investments indicate strong interest in muscle activators and inhibitors.

Strategic partnerships, like with Sanofi, expand market reach and potential revenue.

Significant funding from Royalty Pharma supports commercial launch and R&D advancements.

Land your dream remote job 3x faster with AI

Try Jobo Free